Streetbeat News

Products Services

XAIR

Beyond Cancer, an affiliate of Beyond Air, Inc. (NASDAQ:XAIR), presented first-in-human clinical data for ultra-high concentration nitric oxide (UNO) therapy in solid tumors at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The Phase 1 study showed promising safety profile and clear evidence of immune system activation. Additional Phase 1 data for UNO is expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:10 pm

MOLN

Molecular Partners AG (NASDAQ:MOLN) has presented positive data from its ongoing Phase 1 trial of MP0317 monotherapy in patients with advanced solid tumors at the 2023 SITC Annual Meeting. The data shows that MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment. The monotherapy also shows a favorable safety profile up to the highest planned doses. The company expects to share final results of this study in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

TBIO

Telesis Bio has announced the commercial release of its cell-free amplification kit for the generation of transfection-scale DNA. This product is expected to significantly enhance the company's product portfolio.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

CDTX

Cidara Therapeutics, Inc. (NASDAQ:CDTX) has presented new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data shows the potential of CBO421 to inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies. The company plans to advance this candidate into clinical trials for the treatment of solid tumors.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

XNCR

Xencor has presented preclinical data from multiple XmAb research programs at the SITC Annual Meeting. The company is conducting a Phase 1 study of XmAb808 in patients with advanced solid tumors. Xencor also engineered stabilized, potency-modulated IL-18 cytokines fused to an XmAb heterodimeric Fc domain with Xtend™ Fc technology for longer half-life (IL18-Fc). Further, Xencor's XmAb natural killer cell engagers (NKEs) are multifunctional antibodies that target multiple activating receptors on the surface of NK cells and bind to tumor-associated antigens.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) presented new data on its agenT-797 therapy for solid tumor cancers at the Society for Immunotherapy of Cancer's annual meeting. The therapy showed clinical responses and long-term persistence without toxic pre-conditioning. AgenT-797 is advancing in a randomized phase 2 trial in 2L gastric cancer. The company also plans to launch a randomized phase 2 trial in 2L gastric cancer by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:08 pm

CGEM

Cullinan Oncology will present data at the Society for Immunotherapy of Cancer 2023 Annual Meeting, demonstrating progress across its immunotherapy pipeline. The data includes preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, and highlights the progress of Cullinan's diverse pipeline including CLN-619, CLN-418, CLN-978, and CLN-617.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:08 pm

ABCL

AbCellera has presented new data from its T-cell engager platform at SITC 2023. The data shows that diverse CD3-binding antibodies can optimize T-cell engager function beyond what is possible by modifying a single CD3-binder.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:07 pm

ADAG

Adagene Inc. (NASDAQ:ADAG) presented new data on its masked, anti-CTLA-4 SAFEbody ADG126 at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data demonstrated that ADG126 is effective at targeting CTLA-4 within the tumor microenvironment (TME), resulting in a wider therapeutic index (TI) compared to ipilimumab when combined with anti-PD-1 therapies. The company also reported a clinical case example showing that ADG126 plus pembrolizumab resulted in a confirmed partial response in a patient with advanced/metastatic MSS CRC.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:07 pm

AFMD

Affimed presented preclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, showing that the addition of its innate cell engager (ICE) improves the cytotoxicity of natural killer (NK) and CAR-NK cells. The use of ICE with NK cells eliminates the need for complex and costly manufacturing compared to CAR-NK cells, and offers flexibility to be used with NK cells from different sources.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:06 pm